Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) reported an expansion of their distribution association with the life science operation of Merck KGaA, to now comprise the endpoint PCR and qPCR portfolios1 from Kapa Biosystems. The later firm functions as MilliporeSigma in Canada and the US. Kapa Biosystems was initially bought by Roche last year.
The highlights
The deal will bolster Roche’s existing distribution association with Merck KGaA and enable clients broad access to these offerings via its strong distribution channels. This deal comprises all geographies except Japan, Brazil and the US. It does not comprise Kapa’s NGS products, which continues to be a strong counterpart to the Roche Sequencing Solutions and will persist to be made accessible through company.
The unique PCR enzymes provided under the distribution deal have high tolerance to usual PCR inhibitors, thereby improving speed and specific measures, and enhancing fidelity. These characteristics allow improved workflows and high quality results.
Uwe Oberlander, who is Head of Roche Molecular Diagnostics, said that this deal shows a powerful blend of Kapa’s high-quality qPCR and PCR products with the excellent distribution and e-commerce channels of Merck KGaA. They believe this association will offer improved access to these offerings for researchers in many nations across the world.
Roche is a leading pioneer in diagnostics and pharmaceuticals focused on developing science to enhance people’s lives. It is the largest biotech organization in the world, with truly differentiated medications in oncology, ophthalmology, immunology, infectious diseases and problems of the central nervous system. The company is a leading name in the industry of tissue-based cancer diagnostics and in vitro diagnostics, and a leader in diabetes management. It shows the combined strengths of diagnostics and pharmaceuticals under one roof, which have made company the leader in personalized healthcare.
In the last trading session, the stock price of Roche declined 0.37% to close the day at $27.20. The decline came at a share volume of 1.56 million compared to average share volume of 1.14 million.
